   
 
 
XprESS Eustachian Tube Dilation Study  
 
 
Investigational Plan Number 2909 -001 
 
REVISION C 
September  2015 
 
 
Entellus Medical Inc.  
3600 Holly Lane North, Suite 40 
Plymouth, MN 55447 
 
 
This study will be conducted in accordance with the protocol and applicable regulatory 
requirements.  
  
CONFIDENTIAL INFORMATION 
No use or disclosure of information contained within this document is permitted without prior 
written authorization from Entellus Medical Inc.   

Clinical Investigational Plan   Page ii 
2909-001 Rev C. Entellus Medical Confidential Study Contact Information  
 
Study Sponsor:  
Entellus Medical Inc.  
3600 Holly Lane North, Suite 40 
Plymouth, MN 55447  
Study Contact: 
Robyn Schacherer  
Entellus Medical Inc.  
3600 Holly Lane North, Suite 40 Plymouth, MN 55447 Phone: (763) 463-7054 
Fax: (763) 463-1599 
E-mail: rschacherer@entellusmedical.com
  
  
Clinical Investigational Plan   Page iii 
2909-001 Rev C. Entellus Medical Confidential Investigational Plan Summary  
Title: XprESS Eustachian Tube Dilation  Study 
Study device: XprESS‚Ñ¢ Multi -Sinus Dilation System (XprESS device) 
Study design: A prospective, multicenter , 2-phase, controlled study. Phase 1 consists of a 
nonrandomized  design. Ph ase 2 consists of a randomized design.  
Enrollment:  A total of 50 subjects: 
Phase 1 ‚Äì 10 nonrandomized balloon dilation subjects  
Phase 2 ‚Äì 40 subjects randomized 1:1 to balloon dilation (treatment) or 
continued current medical therapy (control)  
Treatment : Phase 1: All subjects will receive balloon dilation  
Phase 2: Subjects will be randomized 1:1 to the following study arms: 
1. Control arm: Continued current medical management with ability to 
crossover to dilation after 6 weeks, if not improved 
2. Treatment arm: Eustachian tube dilation ‚Äì bilateral or unilateral, as 
indicated 
Clinical centers: Up to 7 US investigational centers  
Inclusion 
criteria: Subjects MUST: 
1. Be ‚â•18 years old 
2. Have been diagnosed with Eustachian tube dysfunction (ETD) for no less 
than 12 months before enrollment with 3 or more of the following 
symptoms: ear pain, ear pressure, ringing in the ears, cracking or popping 
sounds in the ears, muffled hearing, or feeling that ears are clogged or ‚Äúunder water‚Äù 
3. Have an overall ETDQ-7 score ‚â•3.0 
4. Have a record of failed medical management for ETD consisting of a 
minimum of either 4 weeks of daily intranasal steroid spray or 1 completed 
course of an oral steroid within the 12-month period before enrollment 
5. Be a candidate for unilateral or bilateral transnasal  balloon Eustachian tube 
dilation using the XprESS device 
6. Have a temporal bone CT scan (showing the Eustachian tube ) without 
contrast within  6 months of the enrollment date 
7. Be able to read and understand English  
8. Be able and willing to provide consent 
9. Be willing to comply wit h the protocol requirements  
Exclusion 
criteria: Subjects MUST NOT : 
1. Have had any head or neck surgery (eg, adenoidectomy, tonsillectomy) 
including sinonasal surgery or ear tube placement performed within 3 months before  enrollment 
2. Require concomitant procedures a t the time of study enrollment or 
procedure 
3. Have ear tubes in place (tympanostomy tubes, myringotomy tubes, 
ventilation tubes, or pressure equalization tubes ) or perforation of the 
tympanic membrane
 at the time of the study enrollment or procedure 
(patients with healed tympanic membranes after extrusion of tubes are not 
excluded)  
Clinical Investigational Plan   Page iv 
2909-001 Rev C. Entellus Medical Confidential 4. Have patulous Eustachian tubes  
5. Have had any previous laser tuboplasty surgery or microdebridement 
6. Have temporomandibular joint (TMJ)  disorders  
7. Have early hydrops (Meniere‚Äôs disease)  
8. Have had head or neck radiation therapy or sinonasal malignancy  
9. Have a diagnosis of chronic rhinosinusitis (CRS/RARS) that is 
uncontrolled 
10. Have an immunodeficiency  
11. Have craniofacial abnormalities or other anatomical conditions (eg,  
severely deviated septum, tumor, enlarged adenoids or tonsils, severe 
turbinate hypertrophy) that would prevent transnasal  access of the 
Eustachian tubes 
12. Have evidence of internal carotid artery  dehiscence  or anatomic 
abnormalities 
13. Have uncontrolled allergies  
14. Have unmanaged gastroeosophageal reflux disease (GERD) or 
laryngopharyngeal reflux (LPR)  
15. Be pregnant  at the time of study enrollment or procedure  
16. Be currently participating in any other drug or device clinical studies 
excluding post approval or marketing registry studies 
Objective:  To demonstrate the safety and efficacy of the  XprESS device in treating 
patients with ETD . 
Primary  
endpoints : ‚Ä¢ Comparison of mean change in overall ETDQ-7 scores from baseline to 6 
weeks between randomization arms  
‚Ä¢ Complication rate  
Secondary  
endpoint s: ‚Ä¢ Mean change in overall ETDQ-7 score from baseline to follow -up (balloon 
dilation subjects)  
‚Ä¢ Technical success rate  
‚Ä¢ Revision dilation rate  
Study 
assessments  ‚Ä¢ Baseline 
‚Ä¢ 6-Week crossover evaluation (control subjects only)  
‚Ä¢ Procedure 
‚Ä¢ 6-Week postprocedure f ollow-up 
‚Ä¢ 3-Month postprocedure f ollow-up  
‚Ä¢ 6-Month postprocedure f ollow-up (for 510(k) submission and publication 
purposes) 
‚Ä¢ 12-Month postprocedure follow-up (for publication purposes)  
Sponsor:  Entellus Medical Inc.  
United States  
Data 
management and 
monitoring: Entellus Medical Inc.  
United States  
Clinical Investigational Plan   Page v 
2909-001 Rev C. Entellus Medical Confidential Abbreviations and Acronyms  
AE Adverse event  
ANSI American National Standards Institute  
CFR Code of Federal Regulations (US)  
CI Confidence interval  
CRF Case report form  
CRS/RARS  Chronic rhinosinusitis/recurrent acute rhinosinusitis  
CT Computed tomography  
DICOM Digital Imaging and Communications in Medicine  
ENT Ear, nose, and throat  
EQ-5D EuroQol-5 dimension survey  
ET Eustachian tube  
ETD Eustachian tube dysfunction  
ETDQ-7 Eustachian tube dysfunction 7-item questionnaire  
FDA Food and Drug Administration (US)  
GCP Good clinical practices  
GERD Gastroesophageal reflux disease  
HIPAA Health Insurance Portability and Accountability Act of 1996 (US)  
ICF Informed consent form  
IFU Instructions for use  
IRB Institutional Review Board  
LPR Laryngopharyngeal reflux  
PTA Pure tone audiometry  
SAE Serious adverse event  
UADE Unanticipated adverse device effect  
VAS Visual analog scale  
 
ETD Clinical Investigational Plan   Page 6 of 35 
2909-001 Rev C. Entellus Medical Confidential 
 Table of Contents  
Study Contact Information .............................................................................................................. ii 
Investigational Plan Summary  ....................................................................................................... iii 
Abbreviations and Acronyms ......................................................................................................... v  
1 Background and Purpose ........................................................................................................ 8  
1.1 Background ...................................................................................................................... 8  
1.2 Purpose ............................................................................................................................. 8  
2 Protocol ................................................................................................................................... 9  
2.1 Study design ..................................................................................................................... 9  
2.2 Study objective ............................................................................................................... 10  
2.3 Study endpoints  .............................................................................................................. 10  
2.3.1  Primary endpoints  ................................................................................................... 10  
2.3.2  Secondary endpoints ............................................................................................... 10  
2.4 Study size and duration .................................................................................................. 10  
2.5 Study hypothesis ............................................................................................................ 10  
2.6 Sample size estimation  ................................................................................................... 11  
2.7 Data analyses  .................................................................................................................. 11  
2.7.1  Poolability analysis  ................................................................................................. 11  
2.7.2  Missing data  ............................................................................................................ 12  
2.8 Study population ............................................................................................................ 12  
2.8.1  Inclusion criteria  ..................................................................................................... 12  
2.8.2  Exclusion criteria  .................................................................................................... 12  
2.9 Methods and procedures................................................................................................. 13  
2.9.1  Eligibility assessment .............................................................................................. 14  
2.9.2  Baseline visit  ........................................................................................................... 14  
2.9.3  Enrollment............................................................................................................... 15  
2.9.4  Randomization ........................................................................................................ 15  
2.9.5  Control arm assignment .......................................................................................... 15  
2.9.6  Balloon dilation arm assignment and procedure ..................................................... 16  
2.9.7  Follow-up visits ...................................................................................................... 17  
2.9.8  Revision dilations or additional surgery ................................................................. 18  
2.9.9  Early withdrawal and lost to follow-up .................................................................. 18  
2.9.10  End of study ............................................................................................................ 19  
2.10  Study assessments and data collection  ........................................................................... 19  
2.10.1  Primary and secondary endpoint assessments ........................................................ 19  
2.10.2  Other measure assessments  ..................................................................................... 20  
3 Risk/Benefit Analysis  ........................................................................................................... 23  
3.1 Benefits........................................................................................................................... 23  
3.2 Potential risks  ................................................................................................................. 23  
3.3 Risk mitigation  ............................................................................................................... 23  
4 Device Information  ............................................................................................................... 24  
4.1 Investigational device description  .................................................................................. 24  
4.2 Anticipated changes in device design  ............................................................................ 24  
4.3 Investigational device management  ............................................................................... 24  
4.4 Device malfunctions  ....................................................................................................... 24  
Clinical Investigational Plan   Page 7 of 35 
2909-001 Rev C. Entellus Medical Confidential 5 Monitoring Procedures.......................................................................................................... 25  
5.1 Name and address of the Lead Monitor ......................................................................... 25  
5.2 Investigators ................................................................................................................... 25  
5.3 Investigational center monitoring ................................................................................... 25  
6 Adverse Event Definitions and Reporting ............................................................................ 26  
6.1 Adverse events  ............................................................................................................... 26  
6.2 Serious adverse events  ................................................................................................... 26  
6.3 Unanticipated adverse device effects  ............................................................................. 26  
6.4 Assessing, recording, and reporting AEs, SAEs, and UADEs ....................................... 26  
7 Protocol Deviations ............................................................................................................... 28  
8 Labeling ................................................................................................................................ 29  
9 Administrative I nformation  .................................................................................................. 30  
9.1 Investigational center selection  ...................................................................................... 30  
9.2 Training .......................................................................................................................... 30  
9.3 Informed consent process ............................................................................................... 30  
9.4 Confidentiality  ................................................................................................................ 31  
9.5 Institutional Review Board (IRB) .................................................................................. 31  
9.6 Investigator responsibilities ............................................................................................ 31  
9.7 Sponsor responsibilities.................................................................................................. 32  
9.8 Criteria for terminating study  ......................................................................................... 32  
9.9 Criteria for terminating an investigational center  .......................................................... 32  
10 Reports and Records ............................................................................................................. 33  
10.1  Records ........................................................................................................................... 33  
10.2  Reporting requirements .................................................................................................. 33  
11 References  ............................................................................................................................. 35  
 
Table of Tables  
Table 1. Phase 2 Study Assessment Schedule .............................................................................. 13  
Table 2. Preferred Frequency (Hz) Testing Sequence f or Air-bone Conduction Tests ................ 22  
Table 3. Summary of Investigator Reporting Requirements ........................................................ 33  
Table 4. Summary of Sponsor Reporting Requirements .............................................................. 34  
 
  
Clinical Investigational Plan   Page 8 of 35 
2909-001 Rev C. Entellus Medical Confidential 1 Background and Purpose  
1.1 Background  
The Eustachian tube (ET) connects the middle ear to the nasopharynx. It serves 3 functions: 
pressure regulation, deflection of pathogens/foreign objects, and middle ear fluid clearance.1 The 
ET is comprised of a bony isthmus and a cartilaginous region. The cartilaginous part of the ET is normally closed but opens when needed to equalize pressure within the middle ear. Transient opening of the ET occurs with yawning, swallowing, or popping of the ears. 
Dysfunction of the Eustachian tube ca n result from the tube being too open (patulous ET), too 
closed (mechanical obstruction) , or unable to efficiently open during swallowing (functional 
obstruction).
2 Mechanical obstruction of the ET can be from either extrinsic (eg, tumors, 
adenoids, nasal septal deviations ) or intrinsic (eg, inflammation, stenosis) mechanisms. 
Functional obstruction, a common cause of Eustachian tube dysfunction (ETD), occurs whe n the 
tube fails to open in the absence of a mechanical obstruction and can be caused by increased 
tubal compliance, inefficient opening mechanism, and/or abnormal pressures at either ET end.2  
When the ET does not function properly there is abnormal press ure equalization in the middle 
ear. Symptoms of ETD include fullness in the ear, dizziness, tinnitus, and pain or discomfort 
with barometric changes (eg, flying, diving). ETD can lead to tympanic membrane retraction, cholesteatoma, and hearing loss and is frequently associated with chronic otitis media. Chronic rhinosinusitis, allergic rhinitis, gastroesophageal reflux disease, and smoking exposure may all have roles in development of ETD. 
Historically , treatments have been geared toward management  or prevention of otitis media, not 
correcting the dysfunction of the ET. Recently, research has been initiated to study the possibility 
that balloon dilation could offer a minimally invasive treatment for ETD. It is thought that ET balloon dilation increas es the luminal diameter, reduces local inflammation , and facilitate s the 
muscular action necessary for ET opening.
3 Theoretically, balloon dilation results in minimal 
mucosal injury, sparing the clearance and protective functions of the ET, while improving pressure equalization  within the middle ear . 
1.2 Purpose  
The purpose of the current study is to collect 6-month safety and efficacy data on the use of the 
XprESS device to support a 510(k) application to FDA to add a new  indication  for use. Six- and 
12-month data will also be collected for publication purposes. 
  
Clinical Investigational Plan   Page 9 of 35 
2909-001 Rev C. Entellus Medical Confidential 2 Protocol  
2.1 Study design  
The study is a prospective, multicenter, 2-phase, controlled study. P hase 1 will include 10 
subjects treated with b alloon dilation.  
Phase 2 will include  40 subjects randomized 1:1 to balloon dilation or control (6 weeks of  
continued current medical therapy). Phase 2 is designed to test the primary efficacy endpoint 
hypothesis that ETD symptom improvement ( overall ETDQ-7 score) after balloon dilation is 
superior to the control group. For subjects randomized to the control arm , if ETD symptoms 
persist at 6 weeks after randomization ( overall ETDQ-7 score ‚â•3.0 or change <0.4 ), the subjects 
will be allowed to crossover to the balloon dilation arm. Control subjects who do not have 
persistent E TD symptoms at 6 weeks after randomization  will be exited from th e study. Figure 1 
presents the study design and subject flow for Phase 2. 
 
Baseline assessment  
Balloon Dilation Inclusion/exclusion criteria  
Control:  
6 weeks continued current medical therapy  Randomization  
1:1 
6-Week crossover evaluation  
Exit study  6-Week post procedure visit  
3-Month postprocedure visit  
6-Month post procedure visit  
12-Month post procedure visit 
Exit study  
Figure 1. Phase 2 Study Design and Subject Flow  Overall ETDQ -7 ‚â•3.0 
or change <0.4  
No Yes 
Crossover  
&OLQLFDO,QYHVWLJDWLRQDO3ODQ 3DJHRI
5HY& (QWHOOXV 0HGLFDO&RQILGHQWLDO2.2Study objective 
7KHSULPDU\REMHFWLYHRIWKHVWXG\ LVWRGHPRQVWUDWHWKHVDIHW\ DQGHIILFDF\RIWKH;SU(66
GHYLFHIRUWUHDWLQJSDWLHQWVZLW K(XVWDFKLDQWXEHG\VIXQFWLRQ( 7'
2.3Study endpoints 
Primary endpoints 
7KHIROORZLQJPHDVXUHVZLOOEHF ROOHFWHGDVWKHSULPDU\HQGSRLQ WV
x&RPSDULVRQRIPHDQFKDQJHLQRYHU DOO(7'4VFRUHIURPEDVHOLQH WRZHHNVEHWZHHQ
EDOORRQGLODWLRQDUP DQGFRQWURODUP
x&RPSOLFDWLRQUDWH
Secondary endpoints 
7KHIROORZLQJPHDVXUHVZLOOEHFR OOHFWHGDVVHFRQGDU\HQGSRLQWV 
x0HDQFKDQJHLQRYHUDOO(7'4VFR UHIURPEDVHOLQHWRIROORZXS EDOORRQGLODWLRQ
VXEMHFWV
x7HFKQLFDOVXFFHVVUDWH
x5HYLVLRQGLODWLRQUDWH
2.4Study size and duration 
,QLWLDOO\XSWRVXEMHFWVZLOOEH HQUROOHGDWXSWR86LQY HVWLJDWLRQDOFHQWHUVDQGWUHDWHGZLWK
EDOORRQGLODWLRQSKDVH 7KHVHFRQGSKDVH ZLOOLQFOXGHHQURO OPHQWRIDQDGGLWLRQDOVXEMHFWV
UDQGRPL]HGWREDOORRQGLODWLRQRU FRQWLQXHGFXUUHQWPHGLFDO WKHUDS\FRQWURODWXSWR
LQYHVWLJDWLRQDOFHQWHUV$GGLWL RQDOVXEMHFWVPD\EHDGGHGDVQH HGHGXSRQDSSURYDOIURP)'$
,WLVDQWLFLSDWHGWKDWWKH ILUVWVXEMHFWVIURPSKDVHZLOO EHSRROHGZLWKWKHUHPDLQLQJEDOORRQ
GLODWLRQVXEMHFWVIRUWKHILQDODQDO\VLVFRKRUWEDVHGRQVLPLOD ULQFOXVLRQH[FOXVLRQFULWHULDDQG
GDWDFROOHFWLRQ
7KHH[SHFWHGGXUDWLRQRIWKHV WXG\LVWRPRQWKV,WLVHV WLPDWHGWKDWHQUROOPHQWZLOOWDNH
IURPWRPRQWKV:KHQDPLQLPXPRISKDVHVXEMHFWVKDYH FRPSOHWHGZHHNVRI
IROORZXSDQGDPLQLPXPRISKD VHDQGSKDVHVXEMHFWVWUH DWHGZLWKEDOORRQGLODWLRQKDYH
FRPSOHWHGDWOHDVWPRQWKVRI IROORZXSDNDSSOLFDWLRQ ZLOOEHVXEPLWWHGWRWKH)'$WR
REWDLQFOHDUDQFHIRUWKHQHZL QGLFDWLRQ$OOWUHDWHGVXEMHFWVZ LOOFRQWLQXHIROORZXSWKURXJK
PRQWKVIRUSXEOLFDWLRQSXUSRVHV &RQWUROVXEMHFWVZKRGRQRWFU RVVRYHUWRWKHEDOORRQGLODWLRQ
WUHDWPHQWZLOOEHH[ LWHGIURPWKHVWXG\DWZHHNVDIWHUUDQGRP L]DWLRQ
2.5Study hypothesis 
7KHVWXG\LVGHVLJQHGWRWHVWW KHSULPDU\HIILFDF\HQGSRLQWK\S RWKHVLVWKDW(7'V\PSWRP
LPSURYHPHQWDIWHUED OORRQGLODWLRQLVVXSHULRUWRWKHFRQWUROJ URXS
7KHIROORZLQJK\SRWKHVLVZLOOEH WHVWHGLQWKHFRPSDULVRQRIPH DQFKDQJHIURPEDVHOLQHLQ
RYHUDOO(7'4VFRUHVDWZHHNVXV LQJDVLGHG6WXGHQW¬∂VWWH VWZKHUHDSYDOXHOHVVWKDQ
ZLOOEHFRQVLGHUHGVWDWLV WLFDOO\VLJQLILFDQW
&OLQLFDO,QYHVWLJDWLRQDO3ODQ 3DJHRI
5HY& (QWHOOXV 0HGLFDO&RQILGHQWLDO+RG¬ï
+DG:KHUHGLVWKHGLIIHUHQFHEH WZHHQEDOORRQGLOD WLRQDQGFRQWURO JURXSEDOORRQGLODWLRQ¬±
FRQWUROIRUWKHPHDQFKDQJH IURPEDVHOLQHWRZHHNVLQWKHRY HUDOO(7'4VFRUH
2.6Sample size estimation 
7KHVDPSOHVL]HZDVFDOFXODWHGXV LQJ3$66,QHTXDOLW\7HVWVIRU 7ZR0HDQVVDPSOHWWHVWWR
WHVWIRUVXSHULRULW\RILPSURYH PHQWRI(7'4VFRUHVDWZHHNV DQGZDVEDVHGRQWKHIROORZLQJ
DVVXPSWLRQV
x6LJQLILFDQFHOHYHOVLGHGDOSKD 
x3RZHU 
x0HDQFKDQJHLQRYHUDOO(7'4V FRUHLQWKHEDOORRQGLODWLRQJUR XS 
x0HDQFKDQJHLQRYHUDOO(7'4V FRUHLQFRQWUROJURXS 
x&RPPRQVWDQGDUGGHYLD WLRQIRUERWKJURXSV 
8QGHUWKHDVVXPSWLRQVRXWOLQH GDERYHDWRWDOVDPSOHVL]HRI UDQGRPL]HGVXEMHFWVSHU
DUPLVDGHTXDWHWRWHVWWKLVK \SRWKHVLV7RDFFRXQWIRUXSWR DWWULWLRQDPLQLPXPRI
VXEMHFWVZLOOEHHQUROOHG LQ3KDVHRIWKHVWXG\
2.7Data analyses 
6XPPDU\VWDWLVWLFVZLOOEHFDOFX ODWHGIRUDOOVWXG\HQGSRLQWV &DWHJRULFDOYDULDEOHVZLOOEH
VXPPDUL]HGXVLQJIUHTXHQF\GLVWULEXWLRQVDQGFRQWLQXRXVYDULDEO HVZLOOEHVXPPDUL]HGZLWK
PHDQVVWDQGDUGGHYLDWLRQVDQGU DQJHV&RQILGHQFHLQWHUYDOV &,PD\EHFRPSXWHGIRU
VHOHFWVWXG\HQGSRLQWPHDVXUHV 7KHSULPDU\HIILFDF\HQGSRLQWZ LOOEHWHVWHGDWD VLGHGDOSKD
OHYHORI7KHVHFRQGDU\HQGSRL QWRIWKHPHDQFKDQJHLQWK HRYHUDOO(7'4VFRUHIURP
EDVHOLQHWRIROORZXSLQVXEMHFW VWUHDWHGZLWKEDOORRQGLODWLRQ ZLOOEHWHVWHGDW DVLGHGDOSKD
OHYHORI
6XEMHFWVZKRDUHUDQGRPL]HGEXW GURSRXWEHIRUHUHFHLYLQJWKHLU UDQGRPL]HGWU HDWPHQWEDOORRQ
GLODWLRQRUFRPSOHWLRQRI WKHZHHNFRQWLQXHGPHGLFDOWKHUDS\ ZLOOQRWEHLQFO XGHGLQWKHGDWD
DQDO\VLV
Poolability analysis 
3RRODELOLW\RIWKHSULPDU\HIIL FDF\HQGSRLQWEHWZHHQLQYHVWLJDW LRQDOFHQWHUVZLOOEHHYDOXDWHG
7KLVDVVHVVPHQWZLOOHYDOXDWHWKHVLJQLILFDQFHRIDQ\GLIIHUHQF HVRULPEDODQFHVWKDWH[LVWDFURVV
LQYHVWLJDWLRQDOFHQWHUVLQW KHSULPDU\HQGSRLQW&HQWHUVZLWKO HVVWKDQSDWLHQWV HQUROOHGZLOOEH
FRPELQHGLQWRDSVHXGRFHQWHUIRU SXUSRVHVRIDQDO\VLV7RSURWH FWDJDLQVWKDYLQJDQRYHUO\ODUJH
SVHXGRFHQWHUZKHQRQHSVHXGRFHQ WHUH[FHHGVVXEMHFWVDVHFRQ GSVHXGRFHQWHUZLOOEHIRUPHG
7KLVSURFHVVZLOOFRQWLQXHDVQHHGHGHDFKWLPHDSVHXGRFHQWHUH [FHHGVVXEMHFWV
7KHW\SH,,,SYDOXHIURPDQ $129$PRGHOZLOOEHXVHGWRDVVHVV FHQWHUSRRODELOLW\IRUWKH
SULPDU\HIILFDF\H QGSRLQW$QDOSKDOHYHORIZLOOEHXVHG WRDVVHVVVWDWLVWLFDOVLJQLILFDQFHRI
WKHFHQWHUHIIHFW
&OLQLFDO,QYHVWLJDWLRQDO3ODQ 3DJHRI
5HY& (QWHOOXV 0HGLFDO&RQILGHQWLDO
Missing data 
0LVVLQJGDWDFDQLPSDFWWKHLQWHJULW\DQGFUHGLELOLW\RIDQ\FO LQLFDOVWXG\7KHUHIRUHDOODWWHPSWV
ZLOOEHPDGHWRPLQLPL]HPLVVLQJGDWD7KHVHDWWHPSWVLQFOXGHW UDLQLQJRIWKHLQYHVWLJDWRUVDQG
VLWHSHUVRQQHODQGGLVF XVVLRQVZLWKWKHVXEMHFWVGXULQJWKHLQI RUPHGFRQVHQWSURFHVVRQWKH
LPSRUWDQFHRIDFFXUDWHDQGFRPSOHW HGDWDFROOHFWLRQ7KHVWXG\ VSRQVRUZLOOWUDFNLVVXHVZLWK
VLWHVUHJDUGLQJPLVVLQJGDWDWK URXJKWKHXVXDOPRQLWRULQJSURFH VV$QDO\VHVWKDWDFFRXQWIRU
PLVVLQJGDWDZLOOEH FRQGXFWHGRQWKHSULPDU\HIILFDF\HQGSRLQW IRUDFKDQJHIURPEDVHOLQH
2.8Study population 
7KHVWXG\SRSXODWLRQLVSDWLHQWV \HDUVDQGROGHUZLWKPHGLFD OO\UHIUDFWRU\(7'7REH
HOLJLEOHIRUHQUROOPHQWLQWKHVWXG\WKHSDWLHQWVPXVWPHHWDOO WKHLQFOXVLRQFU LWHULDDQGQRQHRI
WKHH[FOXVLRQFULWHULD
Inclusion criteria 
6XEMHFWV0867
 %H¬ï\HDUVROG
 +DYHEHHQGLDJQRVHGZLWK(7'I RUQROHVVWKDQPRQWKVEHIRU HHQUROOPHQWZLWKRU
PRUHRIWKHIROORZLQJV\PSWRPV HDUSDLQHDUSUHVVXUHULQJLQJ LQWKHHDUVFUDFNLQJRU
SRSSLQJVRXQGVLQWKHHDUVPXIIOHGKHDULQJRUIHHOLQJWKDWHD UVDUHFORJJHGRU¬≥XQGHU
ZDWHU¬¥
 +DYHDQRYHUDOO(7'4VFRUH¬ï
+DYHDUHFRUGRIIDLOHGPHGLFDOP DQDJHPHQWIRU(7'FRQVLVWLQJR IDPLQLPXPRI
HLWKHUZHHNVRIGDLO\LQWUDQDVDO VWHURLGVSUD\RUFRPSOHWHG FRXUVHRIDQRUDOVWHURLG
ZLWKLQWKHPRQWKSHUL RGEHIRUHHQUROOPHQW
%HDFDQGLGDWHIRUXQLODWHUDORU ELODWHUDOWUDQVQDVDOEDOORRQ (XVWDFKLDQWXEHGLODWLRQ
XVLQJWKH;SU(66GHYLFH
+DYHDWHPSRUDOERQH&7VFDQVKRZ LQJWKH(XVWDFKLDQWXEHZLWK RXWFRQWUDVWZLWKLQ
PRQWKVRIWKHHQUROOPHQWGDWH
%HDEOHWRUHDGDQGXQGHUVWDQG(QJOLVK
%HDEOHDQGZLOOLQJWRSURYLGHFRQVHQW
%HZLOOLQJWRFRPSO\ZLWKWKHSURWRFROUHTXLUHPHQWV
Exclusion criteria 
6XEMHFWV0867127
+DYHKDGDQ\KHDGRUQHFNVXUJH U\HJDGHQRLGHFWRP\WRQVLOOHF WRP\LQFOXGLQJ
VLQRQDVDOVXUJHU\RUHDUWXEH SODFHPHQWSHUIRUPHGZLWKLQPRQW KVEHIRUHHQUROOPHQW
5HTXLUHFRQFRPLWDQWSURFHGXUHVDWWKHWLPHRIVWXG\HQUROOPHQW RUSURFHGXUH
+DYHHDUWXEHVLQSODFH W\PSDQRVWRP\WXEHVP\ULQJRWR P\WXEHVYHQWLODWLRQWXEHVRU
SUHVVXUHHTXDOL]DWL RQWXEHVRUSHUIRUDWLRQRIWKHW\PSDQLFPHP EUDQHDWWKHWLPHRIWKH
VWXG\HQUROOPHQWRUSURFHGXUHSD WLHQWVZLWKKHDOHGW\PSDQLFPH PEUDQHVDIWHU
H[WUXVLRQRIWXEHVDU HQRWH[FOXGHG
+DYHSDWXORXV(XVWDFKLDQWXEHV
&OLQLFDO,QYHVWLJDWLRQDO3ODQ  3DJHRI
5HY& (QWHOOXV 0HGLFDO&RQILGHQWLDO+DYHKDGDQ\SUHYLRXVODVHUWXERSO DVW\VXUJHU\RUPLFURGHEULGHP HQW
+DYHWHPSRURPDQGLEXODUM RLQW70-GLVRUGHUV
+DYHHDUO\K\GURSV0HQLHUH¬∂VGLVHDVH
+DYHKDGKHDGRUQHFNUDGLDWLRQWKH UDS\RUVLQRQDVDOPDOLJQDQF\ 
+DYHDGLDJQRVLVRIFKURQLFUKLQRVLQXVLWLV&565$56WKDWLVX QFRQWUROOHG
+DYHDQLPPXQRGHILFLHQF\
+DYHFUDQLRIDFLDODEQRUPDOLWLHV RURWKHUDQDWRPLFDOFRQGLWLRQV HJVHYHUHO\GHYLDWHG
VHSWXPWXPRUVHQODUJHGDGHQRL GVRUWRQVLOVVHYHUHWXUELQDWH K\SHUWURSK\WKDWZRXOG
SUHYHQWWUDQVQDVDODFFHVVRI(XVWDFKLDQWXEHV
+DYHHYLGHQFHRILQWHUQDOFDUR WLGDUWHU\GHKLVF HQFHRUDQDWRPLF DEQRUPDOLWLHV
+DYHXQFRQWUROOH GDOOHUJLHV
+DYHXQPDQDJHGJDVWURHRVRSKDJHDOU HIOX[GLVHDVH*(5'RUODU\Q JRSKDU\QJHDO
UHIOX[/35
%HSUHJQDQWDWWKHWLPHRIVWXG\HQUROOPHQWRUSURFHGXUH
%HFXUUHQWO\SDUWLFLSDWLQJLQD Q\RWKHUGUXJRUGHYLFHFOLQLFDO VWXGLHVH[FOXGLQJ
SRVWDSSURYDORUPDUNHWLQJUHJLVWU\VWXGLHV 
2.9Methods and procedures 
6WXG\PHWKRGVDQGSURFHGXUHVDUH GHVFULEHGEHORZ$QRYHUYLHZR IWKHUHTXLUHG3KDVHVWXG\
DVVHVVPHQWVDWHDFKIR OORZXSYLVLWLVSURYLGHGLQ 7DEOH(DFKVXEMHFW¬∂VIROORZXSVFKHGXOHLV
EDVHGRQWKHGDWHRIUDQG RPL]DWLRQFRQWURO DUPRUWKHVWXG\S URFHGXUHEDOORRQGLODWLRQDUP
DQGFURVVRYHUVXEMHFWV
7DEOH3KDVH6WXG\ $VVHVVPHQW6FKHGXOH
Study evaluationBaseline
Within 60 
days of 
procedure
for balloon 
dilation arm6-Week
crossover 
evaluation 
(control arm 
only) 
¬± 7 daysProcedure
Within 60 days 
of baseline or 
6-week 
crossover 
evaluation6-Week 
post 
procedure
¬± 7 days3-Month
post 
procedure
¬± 15 days6-Month post 
procedure
¬± 30 days
(for 510(k) and 
publication)12-Month
post 
procedure
¬± 45 days
(for publication)
,QIRUPHGFRQVHQW 9    
(OLJLELOLW\DVVHVVPHQW 9 9   
'HPRJUDSKLFVKLVWRU\ 9    
&7VFDQZLWKRXWFRQWUDVW 9D    
6\PSWRPVH[DP 9 9  9 9 9 9
0HGLFDWLRQVE 9 9 9 9 9 9 9
1DVDOHQGRVFRS\ 9 9  9 9 9 9
2WRVFRS\H[DPLQDWLRQ 9 9  9 9 9 9
7\PSDQRPHWU\ 9 9  9 9 9 9
9DOVDOYDHYDOXDWLRQ 9 9  9 9 9 9
(4'TXHVWLRQQDLUH 9 9  9 9 9 9
(7'4TXHVWLRQQDLUH 9 9  9 9 9 9
(DULQIHFWLRQDVVHVVPHQW 9F   9 9 9 9
&OLQLFDO,QYHVWLJDWLRQDO3ODQ 3DJHRI
5HY& (QWHOOXV 0HGLFDO&RQILGHQWLDOStudy evaluationBaseline
Within 60 
days of 
procedure
for balloon 
dilation arm6-Week
crossover 
evaluation 
(control arm 
only) 
¬± 7 daysProcedure
Within 60 days 
of baseline or 
6-week 
crossover 
evaluation6-Week 
post 
procedure
¬± 7 days3-Month
post 
procedure
¬± 15 days6-Month post 
procedure
¬± 30 days
(for 510(k) and 
publication)12-Month
post 
procedure
¬± 45 days
(for publication)
$XGLRORJLFH[DPLQDWLRQ 9   9
3UHJQDQF\WHVWZKHQ
DSSOLFDEOH99
3URFHGXUHSDLQ  9G
7HFKQLFDOVXFFHVV   9  
'HYLFHPDOIXQFWLRQ   9   
$GYHUVHHYHQWV  9 9 99  9 9
5HYLVLRQGLODWLRQRU
DGGLWLRQDOVXUJHU\ 9 9 9 9
6XEMHFWVDWLVIDFWLRQ   99  9 9
D7KHHOLJLELOLW\&7VFDQFDQEHSHUIRUPHGZLWKLQPRQWKVRIHQU ROOPHQW
E 2QO\(17UHODWHGPHGLFDWLRQVZLOOEHUHFRUGHGHJDQWLELRWLFV VWHURLGVDOOHUJ\WUHDWPHQWGHFRQJHVWDQWV
F $WEDVHOLQHGHWHUPLQHWKHQXPEHURIHDULQIHFWLRQVLQWKH PRQWKSHULRGEHIRUHHQUROOPHQW
G7KHSDLQVFDOHVKRXOGEHFRPSOHWHGEHIRUHGLVFKDUJHIURPWKHLQ GH[SURFHGXUH6XEMHFWVWUHDWHGXQGHUJHQHUDODQHVWKHVLDDUHQR WUHTXLUHGWRDVVHVV
SURFHGXUHSDLQ
Eligibility assessment 
3DWLHQWVDUHFRQVLGHUHGHOLJLEOHIRUWKLVVWXG\LIWKH\PHHW DOOWKHLQFOXVLRQFULWHULDDQG QRQHRI
WKHH[FOXVLRQFULWHULDDVGHILQHGLQ 6HFWLRQ 7KHSULQFLSDOLQYHVWLJDW RURUVXELQYHVWLJDWRUDW
HDFKLQYHVWLJDWLRQDOFHQWHUZLOOGHWHUPLQHSDWLHQWHOLJLELOLW\ EDVHGRQWKHLQFOXVLRQH[FOXVLRQ
FULWHULD
$OOSRWHQWLDOVXEMHFWVPXVWKDYHD &7VFDQZLWKRXWFRQWUDVWR IWKHWHPSRUDOERQHGRQHZLWKLQ
PRQWKVEHIRUHVWXG\HQUROOPHQW7KH&7VFDQPXVWLQFOXGHFRURQD ODQGD[LDOLPDJHVRIWKH
WHPSRUDOERQHLQFOXGLQJWKH(XVW DFKLDQWXEH7ZRHOHFWURQLFFRS LHVLQ',&20IRUPDWRIWKH&7
VFDQPXVWEHDYDLODEO HFRS\WREHUHWDLQHGE\WKHLQYHVWLJDW LRQDOFHQWHUDQGFRS\WREH
UHWULHYHGE\WKHVSRQVRU
Baseline visit 
$OOFDQGLGDWHVIRUWKHVWXG\ZLOO KDYHWKHIROORZLQJEDVHOLQHF OLQLFDOHYDOXDWLRQVGRQH EHIRUH
HQUROOPHQWDQGUDQGRPL]DWLRQ 
x,QIRUPHGFRQVHQWVLJQHG
x%DVHOLQHPHGLFDOKLVWRU\GHPRJU DSKLFVV\PSWRPVDQGPHGLFDWLR QKLVWRU\LQWKH
PRQWKSHULRGEHIRUHHQUROOPHQW
x(OLJLELOLW\DVVHVVPHQWVXEMHFWVPHHWDOOLQFOXVLRQDQGQRH[FO XVLRQFULWHULD
x1DVDOHQGRVFRS\
x2WRVFRS\H[DPLQDWLRQ
x7\PSDQRPHWU\
x9DOVDOYDHYDOXDWLRQ
&OLQLFDO,QYHVWLJDWLRQDO3ODQ 3DJHRI
5HY& (QWHOOXV 0HGLFDO&RQILGHQWLDOx$VVHVVPHQWRIHDULQIHFWLRQVRYH UWKHPRQWKSHULRGEHIRUHHQ UROOPHQW
x$XGLRORJLFH[DPLQDWLRQLQFOXGLQJ DSXUHWRQHDXGLWRU\37$WHV W
x(4'DQG(7'442/TXHVWLRQQDLUHV FRPSOHWHGE\WKHVWXG\VXE MHFW
x3UHJQDQF\WHVWIRUIHPDOHVXEM HFWVRIFKLOGEHDULQJSRWHQWLDO
7KHUHVXOWVRIDOOEDVHOLQHHY DOXDWLRQVZLOOEHGRFXPHQWHGRQW KHDSSURSULDWH&D VH5HSRUW)RUPV
&5)V
)RUVXEMHFWVXQGHUJRLQJEDOORRQGLODWLRQSUHSURFHGXUHDQWLELRW LFVDQGVWHURLGVPD\EH
SUHVFULEHGDWWKHGLVFUHWLRQRIWK HVWXG\SK\VLFLDQ0HGLFDWLRQ VPD\EHSUHVFULEHGWRWUHDWDFWLYH
LQIHFWLRQVDQGSURFHGXUHVPD\EH UHVFKHGXOHGXQWLODFWLYHLQIHF WLRQVUHVROYH
Enrollment 
$SDWLHQWZLOOEHFRQVLG HUHGHQUROOHGLQWKHV WXG\DIWHUWKHED VHOLQHDVVHVVPHQWRQFHDOOWKH
LQFOXVLRQH[FOXVLRQFULWHULD KDYHEHHQPHWD QGDWWKHWLPHRIU DQGRPL]DWLRQ
Randomization 
5DQGRPL]DWLRQDVVLJQPHQWVZLOOEHJHQHUDWHGE\DQLQGHSHQGHQWV WDWLVWLFLDQXVLQJDGLVWULEXWLRQ
LQYDULDEOHEORFNVVL]HVIRUHDFKFHQWHUZLWKDDOORFDWLRQ WRFRQWURORUEDOORRQGLODWLRQ7KH
PDVWHUUDQGRPL]DWLRQOLVWZLOOEHVWRUHGE\WKH6SRQVRU5DQGRP L]DWLRQDVVLJQPHQWVZLOOEH
SODFHGLQWRVHTXHQWLDOO\QXPEHUHGDQGVHDOHGHQYHORSHV7KHWUD LQHGVWXG\FHQWHUSHUVRQQHOZLOO
FRQWDFW6SRQVRUWRUHFHLYHWKHUDQGRPL]DWLRQDVVLJQPHQWDIWHUW KHIROORZLQJVWHSVKDYHEHHQ
FRPSOHWHG
$OOEDVHOLQHHYDOXDWLRQV KDYHEHHQSHUIRUPHG
6XEMHFWKDVEHHQGHWHUPLQHGHOLJLE OHIRUWKHVWX G\LHLQFOXVL RQH[FOXVLRQFULWHULD
UHYLHZHG
6XEMHFWKDVVLJQHGDQ,QIRUPHG&RQVHQW
7KH6SRQVRUZLOOUHWULHYHWKHILUVWRUQH[WVHTXHQWLDOO\QXPE HUHGHQYHORSHIRUWKDWFHQWHUDQG
RSHQLW7KHUDQGRPL]DWLRQDVVLJQPHQWLQFOXGLQJWKHUDQGRPL]DW LRQ,'QXPEHUDQGWUHDWPHQW
DVVLJQPHQWZLOOEHUHFRUGHGRQWKH5DQGRPL]DWLRQ(QUROOPHQW&D VH5HSRUW)RUP7KH6SRQVRU
SHUVRQQHOZLOOUHFRUGWKHVXEMHFW,'LQWKHUDQGRPL]DWLRQORJ
Control arm assignment 
6XEMHFWVUDQGRPL]HGWRWKHFRQWURO DUPZLOOFRQWLQXHWKHLUFXUU HQW(7'PHGLFDOWUHDWPHQW
UHJLPHQIRUZHHNVDIWHUUDQGR PL]DWLRQ$WUHDWPHQWUHJLPHQFR QVLVWLQJRIQRPHGLFDWLRQLV
SHUPLWWHGLIFRQVLVWHQWZLWKWKHVXEMHFW¬∂VFXUUHQWWUHDWPHQWSO DQ0HGLFDWLRQVZ LOOEHGRFXPHQWHG
RQWKH0HGLFDWLRQV&5)&RQWUR OVXEMHFWVDUHQRWDOORZHGWRXQG HUJRDQ\VXUJLFDOWUHDWPHQWV
GXULQJWKLVVWXG\SHULRG
$IWHUWKHZHHNSHULRGRIFRQ WLQXHGPHGLFDOWKHUDS\FRQWUROV XEMHFWVZKRFRQWLQXHWRKDYH
(7'V\PSWRPVGHILQHGDVDQRYH UDOO(7'4VFRUH¬ïRUDFKDQ JHRIZLOOEHDOORZHG
WRFURVVRYHUWREDOORRQGLODWL RQWUHDWPHQWDQGZLOOXQGHUJRWKH GLODWLRQSURFHGXUHDQG
SRVWSURFHGXUHIROORZXSYLVLWVF KHGXOHIRUWKHEDOORRQGLODWLRQ DUP&RQWUROVXEMHFWVZKRGRQRW
&OLQLFDO,QYHVWLJDWLRQDO3ODQ 3DJHRI
5HY& (QWHOOXV 0HGLFDO&RQILGHQWLDOFURVVRYHUZLOOEHH[LWHGIURPWKHVWXG\DWWKLVWLPH7KHZHH NFURVVRYHUHYDOXDWLRQZLOOVHUYH
DVWKHSUHSURFHGXUHDVVHVVPH QWIRUFURVVRYHUVXEMHFWV
Balloon dilation arm assi gnment and procedure 
6XEMHFWVVKRXOGXQGHUJRWKHEDOO RRQGLODWLRQSURFHGXUHZLWKLQ GD\VRIWKHEDVHOLQH
DVVHVVPHQWUDQGRPL]HGWREDOORRQG LODWLRQRUWKHZHHNFURVV RYHUHYDOXDWLRQFURVVRYHU
VXEMHFWV$OOIHPDOHVXEMHFWVRI FKLOGEHDULQJSRWHQWLDODUHUH TXLUHGWRKDYHDQHJDWLYHEORRGRU
XULQHSUHJQDQF\WHVW ZLWKLQGD\VEHIRUHDEDO ORRQGLODWLRQSURFHGXUH 
5HIHUWRWKH;SU(66,QVWUXFWLRQV IRU8VH,)8IRUVSHFLILFLQV WUXFWLRQVRQV\VWHPSUHSDUDWLRQ
VXEMHFWSUHSDUDWLRQGHYLFHVHW XSVKDSLQJWKHGHYLFHDQGGHW DLOHGWUHDWPHQWSURFHGXUHIRUXVLQJ
;SU(66WRSHUIRUP(XVWDFKLDQWXEHGLODWLRQ
3URFHGXUHVLWHRIVHUYLFH
,QYHVWLJDWRUVPD\FKRRVHWRFRP SOHWHVWXG\SURFHGXUHVXQGHUJHQ HUDOSOXVORFDODQHVWKHVLDLQD
VXUJLFDOVHWWLQJRUXQGHUORFDOD QHVWKHVLDDORQHLQWKHRIILFH VHWWLQJEDVHGRQWKHLUPHGLFDO
GLVFUHWLRQDQGVXEMHFWWROHUDQFH ,IWKHVWXG\SURFHGXUHLVILU VWDWWHPSWHGLQWKHRIILFHVHWWLQJEXW
FDQQRWEHFRPSOHWHGXQGHUORFDOD QHVWKHVLDDORQHGXHWRVXEMHFW WROHUDQFHWKH VXEMHFWPD\EH
WUHDWHGXQGHUJHQHUDODQHVWKHVLD LQDVXUJLFDOVHWWLQJZLWKRXW EHLQJZLWKGUDZQIURPWKHVWXG\
6XFKFDVHVZLOOQRWEHFRQVLGHUHG WUHDWPHQWIDLOXUHV3URFHGXUH VFRQYHUWHGIURPORFDODQHVWKHVLD
DORQHWRJHQHUDODQHVWKHVLDZLOO EHGRFXPHQWHGRQWKH3URFHGXUH &5)
3URFHGXUHDQHVWKHVLD
$QHVWKHVLDVKRXOGEHDGPLQLVWHUH GDSSURSULDWHO\WRDOORZVXEMHF WWROHUDQFHDQGEDVHGRQWKH
WUHDWLQJSK\VLFLDQ¬∂VPHGLFDOWUD LQLQJ3K\VLFLDQVPD\FKRRVHWR XVHJHQHUDODQGRUORFDO
DQHVWKHVLDUHJLPHQVWKDWZLOOD OORZVDIHDQGWROHUDEOHXVHRIW KHGHYLFHLQWKHVXEMHFW7\SHRI
DQHVWKHVLDDQGORFDWLRQRIORFDO LQMHFWLRQVZLOOEHGRFXPHQWHG 
(XVWDFKLDQWXEHDVVHVVPHQW
$WHPSRUDO&7VFDQZLWKD[LDOD QGFRURQDOYLHZVSHUIRUPHGZLWKL QWKHODVWPRQWKVEHIRUH
VWXG\HQUROOPHQWZLOOEHUHYLHZH GWRHQVXUHWKHUHDUHQRDQDWRP LFDQRPDOLHVWKDWZRXOGSUHYHQW
WUDQVQDVDODFFHVVWRWKH(XVWDFK LDQWXEHRUSXWWKHVXEMHFWDW LQFUHDVHGULVNHJGHKLVFHQFHRIWKH
FDURWLGDUWHU\,IVXFKFRQG LWLRQVH[LVWWKHVXEMHFWLVQRWH OLJLEOHIRUWKHVWXG\
'HYLFHVL]HVHOHFWLRQ
,QYHVWLJDWRUVPD\FKRRVHWKH ;SU(66GHYLFHVL]HEDVHGRQWKHLU PHGLFDONQRZOHGJHDQGWKH
VXEMHFW¬∂V(XVWDFKLDQWXEHDQDWR P\$OOEDOORRQVL]HVDUHDSSURS ULDWHIRUWUHDWLQJ(XVWDFKLDQ
WXEHVVHOHFWLRQLVEDVHGRQSK\VLF LDQSUHIHUHQFH7KH;SU(66G HYLFHVL]HVDUHOLVWHGLQ 6HFWLRQ

(XVWDFKLDQWXEHEDOORRQGLODWLRQ
7KH;SU(66EDOORRQLVGHVLJQHGIRU DWUDQVQDVDODSSURDFKRQO\ 3URFHGXUDOLQIRUPDWLRQRQ
GHYLFHXVHLVSURYLGHGLQWKH;SU(66,)8
7KHIROORZLQJGDWDZLOOEHFROOHFWHGGXULQJWKHVWXG\SURFHGXUH DQGGRFXPHQWHGRQWKH
DSSURSULDWH&5)V
&OLQLFDO,QYHVWLJDWLRQDO3ODQ 3DJHRI
5HY& (QWHOOXV 0HGLFDO&RQILGHQWLDOx6LWHRIVHUYLFH
x$GPLVVLRQDQGGLVFKD UJHGDWHWLPHV
x3URFHGXUHVWDUWVWRSWLPHV
x7\SHRIDQHVWKHVLDDQGORFDWLRQ DQGGRVDJHRIDQ\ORFDOLQMHFWL RQV
x,GHQWLILFDWLRQRIDOO;SU(66GHYLFHVXVHG
x7HFKQLFDOVXFFHVVIRU;SU(66GHYLFH
x7RWDOQXPEHURIEDOO RRQLQIODWLRQVIRUHDFKWUHDWPHQWVLGH
x7RWDOGXUDWLRQRIEDOO RRQLQIODWLRQVLQVHFRQGVIRUHDFKWUHD WPHQWVLWH
x3URFHGXUHVWKDWFRQYHUWIURPOR FDODQHVWKHVLDDORQHWRJHQHUDO DQHVWKHVLD
x3URFHGXUHSDLQVFRUHIRUVXEM HFWVWUHDWHGXQGHUORFDODQHVWKHV LDDORQHQRWUHTXLUHGIRU
VXEMHFWVZKRDUHWUHDWHG XQGHUJHQHUDODQHVWKHVLD
x$GYHUVHHYHQWV
x'HYLFHPDOIXQFWLRQV
3RVWSURFHGXUHFDUH
3RVWSURFHGXUHFDUHLQFOXGLQJPHG LFDOPDQDJHPHQWLVDWWKHGLV FUHWLRQRIWKHSK\VLFLDQ
3RVWSURFHGXUHPHGLFD ODQGFOLQLFDOPDQDJHP HQWZLOOEHFROOHFWHG RQWKH0HGLFDWLRQ&5)DWWKH
ZHHNSRVWSURFHGXUHYLVLW 
&RQFRPLWDQWSURFHGXUHV
&RQFRPLWDQWSURFHGXUHVDUHQRWD OORZHGLQWKLVVWXG\6SHFLILFD OO\VXEMHFWVUDQGRPL]HGWRWKH
FRQWURODUPDUHQRWDOORZHGWRXQGH UJRDQ\VXUJLFDOSURFHGXUHV RIWKHHDUVRUVLQXVHVGXULQJWKH
ZHHNSHULRGRIFRQWLQXHGPHGLFDOWKHUDS\
Follow-up visits 
6XEMHFWVUDQGRPL]HGWRWKHFRQWURO DUPDUHVFKHGXOHGIRUDIROO RZXSYLVLWDWZHHNV¬ìGD\V
DIWHUWKHLUUDQGRPL]DWLRQ$WWK LVYLVLWFRQWUROVXEMHFWVZLOO EHHYDOXDWHGDQGLIWKHLU(7'
V\PSWRPVSHUVLVWGHILQHGDV RYHUDOO(7'4VFRUH¬ïRUFKDQJH WKHVXEMHFWVDUHHOLJLEOH
IRUFURVVRYHUWREDOORRQGLOD WLRQWUHDWPHQW6XEMHFWVZKRGRQR WKDYHSHUVLVWHQW(7'V\PSWRPV
DUHH[LWHGIURPWKHVWXG\DIWHUFRPSOHWLRQRIWKLVYLVLW
6XEMHFWVUDQGRPL]HGWREDOORRQG LODWLRQDQGFURVVRYHUVXEMHFWV DUHVFKHGXOHGIRUWKHIROORZLQJ
SRVWSURFHGXUHIROORZXSYLVLWVZLQGRZ
x:HHN¬ìGD\V
x0RQWK¬ìGD\V
x0RQWK¬ìGD\V
x0RQWK¬ìGD\V
7KHIROORZLQJDVVHVVPHQWVDUHU HTXLUHGDWDOOIROORZXSYLVLWV 
x6\PSWRPDVVHVVPHQW
x1DVDOHQGRVFRS\H[DPLQDWLRQ
x2WRVFRS\H[DPLQDWLRQ
&OLQLFDO,QYHVWLJDWLRQDO3ODQ 3DJHRI
5HY& (QWHOOXV 0HGLFDO&RQILGHQWLDOx7\PSDQRJUDP
x9DOVDOYDHYDOXDWLRQ
x0HGLFDWLRQXVHVLQFHODVWVWXG\YLVLW
x(DULQIHFWLRQVVLQFHODVWVWXG\YLVLW
x5HYLVLRQGLODWLRQRUDGGLWLRQDOVXUJHU\
x6XEMHFWVDWLVIDFWLRQ
x(4'
x(7'4
x$GYHUVHHYHQWV
,QDGGLWLRQWRWKHDVVH VVPHQWVQRWHGDERYHDQ DXGLRORJLFH[DPLQDWLR QLVUHTXLUHGDWWKH
PRQWKYLVLW 
Revision dilations or additional surgery 
5HYLVLRQGLODWLRQVRURWKHUVXUJ LFDOSURFHGXUHVDUHSHUPLWWHGI RUVXEMHFWVZKRGRQRWH[SHULHQFH
UHOLHIRI(7'V\PSWRPVDIWHU EDOORRQGLODWLRQWUHDWPHQW+RZHYH ULWLVUHFRPPHQGHGWKDW
UHYLVLRQSURFHGXUHVDUHQRWSHUIRUP HGEHIRUHWKHPDMRULW\RIWL VVXHKHDOLQJUHPRGHOLQJKDVEHHQ
DOORZHGWRRFFXU7KLVSURFHVV FDQWDNHXSWRPRQWKVDIWHUWK HLQLWLDOSURFHGXU H6WDQGDUGRI
FDUHPHGLFDOWUHDWPHQWLVSHUPLWWHGDWDQ\WLPHGXULQJWKHVWXG \WRDGGUHVVVXEMHFWV\PSWRPV
,IDVXEMHFWKDVDUHYLVLRQGLOD WLRQRUDGGLWLRQDO(17VXUJHU\ GXULQJWKHSRVWSURFHGXUHIROORZXS
SHULRGWKHLQYHVWLJDWLRQDOFHQWH UVKRXOGPDNHHYHU\HIIRUWWR FROOHFWWKHSURFHGXUHRSHUDWLYH
QRWHVIRUWKHSURFHGXUHV7KH GDWHDQGW\SHRISURFHGXUHSHUI RUPHGZLOOEHGRFXPHQWHGRQWKH
5HYLVLRQ'LODWLRQ$GGLWLRQDO6XUJ HU\&5)$FRS\RIWKHGHLGHQW LILHGUHYLVLRQSURFHGXUHQRWHV
ZLOOEHUHWULHYHGIRUW KHVSRQVRUVWXG\ILOHV
Early withdrawal and lost to follow-up 
6WXG\VXEMHFWVDUHIUHHWRZLWKGUDZIURPWKHLQYHVWLJDWLRQDWD Q\WLPHZLWKRXWKDYLQJWRMXVWLI\
WKHLUUHDVRQVDQGZLWKRXWDIIHFWLQ JWKHLUUHODWLRQVKLSZLWKWKH LQYHVWLJDWRU$QLQYHVWLJDWRUPD\
DOVRZLWKGUDZDVXEMHFWIURPWKHVWXG\DWDQ\WLPHLILWLVGHW HUPLQHGWREHLQWKHVXEMHFW¬∂VEHVW
LQWHUHVWV
$VXEMHFW¬∂VIXWXUHPDQDJHPHQWZ LOOQRWEHFKDQJHGE\DGHFLVLRQ YROXQWDU\RURWKHUZLVHWR
ZLWKGUDZIURPWKHVWXG\$OOU HDVRQDEOHHIIRUWVVKRXOGEHPDGH WRUHWDLQVXEMHFWVXQWLO
FRPSOHWLRQRIWKHFOLQLFDOVWXG\ 5HDVRQVIRUWHUPLQDWLRQRUZL WKGUDZDOLQFOXGHEXWDUHQRW
OLPLWHGWRWKHIROORZLQJ
x6XEMHFWGHDWK
x6XEMHFWUHTXHVW
x6XEMHFWORVWWRIROORZXS$VXEM HFWLVFRQVLGHUHG¬≥ORVWWRIRO ORZXS¬¥DIWHUDPLQLPXPRI
GRFXPHQWHGDWWHPSWVWRUHDFKWKH VXEMHFWE\SKRQHFDOOE\DP HPEHURIWKHVWXG\VWDII
DQGDQXQDQVZHUHGFHUWLI LHGOHWWHUVHQWWRWKHVXEMHFW¬∂VODVWN QRZQDGGUHVVE\DWUDFHDEOH
PHWKRGHJFHUWLILHGPDL OFRXULHUFRPPHUF LDOVKLSSLQJWUDQVS RUWFRPSDQ\
x6XEMHFW¬∂VSDUWLFLSDWLRQWHUPLQ DWHGE\WKHLQYHVWLJDWRU
&OLQLFDO,QYHVWLJDWLRQDO3ODQ 3DJHRI
5HY& (QWHOOXV 0HGLFDO&RQILGHQWLDOx6WXG\WHUPLQDWHGE\WKHVSRQVRU
)RUDQ\VXEMHFWVZLWKHDUO\Z LWKGUDZDORUWHUPLQDWLRQWHUPLQDW LRQLQIRUPDWLRQZLOOEHUHFRUGHG
LQWKHVXEMHFW¬∂VUHFRUGVDQGWKHGD WHRIODVWFRQWDFWZLWKWKH VXEMHFWQRWHGRQWKH(QGRI6WXG\
&5)
End of study
6XEMHFWVUDQGRPL]HGWRWKHFRQWUR ODUPZKRGRQRWFURVVRYHUWR EDOORRQGLODWLRQWU HDWPHQWDUH
H[LWHGXSRQFRPSOHWLRQRIWKH ZHHNFURVVRYHUHYDOXDWLRQ
3DUWLFLSDWLRQLQWKHVWXG\LVF RQVLGHUHGFRPSOHWHIRUDOOEDOOR RQGLODWLRQDQGFURVVRYHUVXEMHFWV
XSRQFRPSOHWLRQRIWKHPRQW KSRVWSURFHGXUHYLVLW
,IDVXEMHFWKDVDQ;SU(66GHYL FHLQVHUWHGWUDQVQDVDOO\EXWGRH VQRWXQGHUJRDEDOORRQGLODWLRQ
SURFHGXUHWKHVXEMHFWZLOOEH IROORZHGWRWKHZHHNSRVWSURFH GXUHYLVLWDQGWKHQGLVFRQWLQXHG
IURPWKHVWXG\XQOHVVWKHVXEMHFWKDVDQRQJRLQJDGYHUVHHYHQW $(,IWKHVXEMHFWKDVDQ
RQJRLQJ$(DWWKHZHHNSRVWSUR FHGXUHYLVLWWKHVXEMHFWZLOO EHIROORZHGXQWLO$(UHVROXWLRQRU
PRQWKVSRVWSURFHGXUHZ KLFKHYHUFRPHVILUVW
$Q(QGRI6WXG\&5)ZLOOEHFRP SOHWHGZKHQWKHVXEMHFWKDVFRPS OHWHGWKHLUODVWUHTXLUHG
IROORZXSYLVLWRUDWWKHWLPHRIZ LWKGUDZDORUORVWWRIROORZ XSLIWKHVXEMHFWGLVFRQWLQXHVWKH
VWXG\SUHPDWXUHO\
2.10Study assessments and data collection 
6WXG\GDWDZLOOEHFR OOHFWHGDFFRUGLQJWR*RRG&OLQLFDO3UDFWLF HVXVLQJSDSHU&5)VFRPSOHWHGDW
WKHLQYHVWLJDWLRQDOFHQWHU&5)VZLOOEHFROOHFWHGIURPWKHFHQ WHUVDQGZLOOEHHQWHUHGLQWRD
&OLQ'H[GDWDEDVHE\(QWHOOXVVWD IIXVLQJSDVVHQWU\SURFHGXUH V7KHGDWDZLOOEHUHYLHZHGE\
(QWHOOXVVWDIIDQGDQ\TXHULHV ZLOOEHGRFXPHQWHGDQGVXEPLWWHG WRWKHLQYHVWLJDWL RQDOFHQWHUIRU
FODULILFDWLRQ
7KHUHTXLUHGVWXG\DVVHVVPHQWVIRUHDFKVSHFLILHGLQWHUYDODUH RXWOLQHGLQWKH 6HFWLRQ 6HH
7DEOHIRUDQRYHUYLHZRIWKH UHTXLUHGVWXG\DVVHVVPHQWVDWHDFKIROO RZXSYLVLW(DFKVXEMHFW¬∂V
IROORZXSVFKHGXOHLVEDVHGRQWKH GDWHRIUDQGRPL] DWLRQFRQWU RODUPRUWKHVWXG\SURFHGXUH
EDOORRQGLODWLRQDQGFURVVRYHUDUPV
Primary and secondary endpoint assessments 
0HDQFKDQJHLQRYHUDOO(7'4VFRUH
7KH(XVWDFKLDQ7XEH'\VIXQFWLRQ4XH VWLRQQDLUH(7'4LVDVWD QGDUGL]HGLWHP
TXHVWLRQQDLUHGHVLJQH GWRDVVHVVTXDOLW\RIOLIHDVVRFLDWHGZLW K(XVWDFKLDQWXEHG\VIXQFWLRQ7KH
GLPHQVLRQVRIWKHTXHVWLRQQDLUH DUHSUHVVXUHSDLQIHHOLQJF ORJJHGFROGVLQXVLWLVSUREOHPV
FUDFNOLQJSRSSLQJULQJLQJDQGI HHOLQJPXIIOHG(DFKLWHPLVD VVHVVHGRQDQRSUREOHPWR
VHYHUHSUREOHPVFDOHDQGDQRYHUD OOVFRUHZKLFKLVWKHPHDQ RIWKHGLPHQVLRQVFRUHVLV
FDOFXODWHG7KHTXHVWLRQQDLUHLV GHVLJQHGWREHVHOIFRPSOHWHG E\WKHVXEMHFW(7'4
TXHVWLRQQDLUHVZLOOEHF RPSOHWHGDWEDVHOLQH DQGDWDOOVWXG\Y LVLWV&KDQJHVLQRYHUDOO(7'4
VFRUHVZLOOEHEDVHGRQW KHPHDQFKDQJHEHWZHHQWKHEDVHOLQHDV VHVVPHQWRUZHHNFURVVRYHU
&OLQLFDO,QYHVWLJDWLRQDO3ODQ 3DJHRI
5HY& (QWHOOXV 0HGLFDO&RQILGHQWLDOHYDOXDWLRQIRUFURVVRYHUVXEM HFWVDQGHDFKIROORZXSDVVHVVPHQ W6WDQGDUGWUHDWPHQWHIIHFWVL]H
PD\DOVREHFDOFXODWHGIRUWKH PHDQRYHUDOO(7'4VFRUH7KH( 7'4&5)PD\EH
FRQVLGHUHGDVRXUFHGRFXPHQWLIF RPSOHWHGGLUHFWO\E\WKHVXEMH FWRQWKH&5)
&RPSOLFDWLRQUDWH
$FRPSOLFDWLRQLVGHILQHGDVDVH ULRXVDGYHUVHHYHQWWKDWLVGH YLFHUHODWHGRUSURFHGXUHUHODWHGDV
QRWHGLQ6HFWLRQ7KHSDUDPHWHURILQWHUHVWLVW KHSHUFHQWRIVXEMHFWVZKRH[SH ULHQFHRUPRUH
FRPSOLFDWLRQVIURPWKHWLPHRIWKHLQGH[SURFHGXUHWKURXJKWKH PRQWKIROORZXS
7HFKQLFDOVXFFHVV
7HFKQLFDOVXFFHVVZLOOEHFROOHFW HGIRUHDFK(XVWDFKLDQWXEHLQ ZKLFKGLODWLRQLVDWWHPSWHG
6XFFHVVRIWKH;SU(66GHYLFHZLOO EHFDOFXODWHGDVWKHQXPEHUR IVXFFHVVIXOGLODWLRQVGLYLGHGE\
WKHQXPEHURI(7VZLWKGLODWLRQD WWHPSWV6XFFHVVLVGHILQHGDV DQDWWHPSWZKHUHWKH;SU(66
GHYLFHLVVXFFHVVIXOO\GHOLYHUH GWRWKHWDUJHWORFDWLRQLQIODW HGGHIODWHGDQGZLWKGUDZQIURPWKH
WUHDWHG(XVWDFKLDQWXEH
5HYLVLRQGLODWLRQUDWH
5HYLVLRQGLODWLRQLVGHILQHGDV DQ\UHSHDWEDOORRQGLODWLRQSUR FHGXUHSHUIRUPHGRQDQ(7WKDW
ZDVLQLWLDOO\WUHDWHGZLWKDQ;SU (66GHYLFH7KHSDUDPHWHURIL QWHUHVWLVWKHSHUFHQWRIVXEMHFWV
ZKRH[SHULHQFHRUPRUHUHYLV LRQGLODWLRQVGXULQJWKHVWXG\
Other measure assessments 
*HQHUDOTXDOLW\RI OLIHDVVHVVPHQW
4XDOLW\RIOLIHUHJDUGLQJJHQH UDOKHDOWKZLOOEH DVVHVVHGXVLQJ WKH(XUR4RO(4'
7KH(4'LVDVWDQGDUGL]HGTXHVW LRQQDLUHXVHGWRHYDOXDWHJHQH UDOKHDOWKUHODWHGTXDOLW\RIOLIH
7KHTXHVWLRQQDLUHLVPDGHXSRI TXHVWLRQVIRUHDFKKHDOWK GLPHQVLRQPHDVXUHGPRELOLW\
VHOIFDUHXVXDODFWLY LWLHVSDLQGLVFRPIRU WDQGDQ[LHW\GHSUH VVLRQDQGDYLVXDODQDORJVFDOH
9$6WRLQGLFDWHRYHUDOOK HDOWKRQDVFDOHRIWR(DFKK HDOWKGLPHQVLRQKDVSRVVLEOH
UHVSRQVHVQRSUREOHPVVOLJKWSU REOHPVPRGHUDWHSUREOHPVVHY HUHSUREOHPVRUH[WUHPH
SUREOHPV7KHTXHVWLRQQDLUHLVGH VLJQHGWREHVHOIFRPSOHWHGE\ WKHVXEMHFW7KH(4'
TXHVWLRQQDLUHZLOOEHF RPSOHWHGDWDOOVWXG \YLVLWV7KH(4' &5)PD\EHFRQVLGHUHGDVRXUFH
GRFXPHQWLIFRPSOHWHGGLUHFW O\E\WKHVXEMHFWRQWKH&5)
3URFHGXUHSDLQ
7KHSURFHGXUHSDLQDVVHVVPHQWZ LOOEHFROOHFWHGE HIRUHGLVFKDUJ HIURPHDFKVXEMHFWZKR
XQGHUJRHVWKHGLODWLRQSURFHGXUH ZLWKORFDODQHVWKHVLDDORQH3 DLQZLOOEHDVVHVVHGXVLQJDQ
SRLQW9$67KH3URFHGXUH&5)PD\ EHFRQVLGHUHGWKHVRXUFHGRFXP HQWIRUWKHSURFHGXUHSDLQ
DVVHVVPHQW
2WRVFRS\ILQGLQJV
2WRVFRS\H[DPLQDWLRQVZLOOEHSH UIRUPHGDWEDVHOLQHDQGDWHDFK IROORZXSYLVLW7KH
H[DPLQDWLRQZLOOLQFOXGHDVVHVVPHQW RIWKHW\PSDQLFPHPEUDQHH DUGUXPIRUFRORU
WUDQVOXFHQF\PRELOLW\VKDSH EXOJLQJUHWUDFWLRQDQGWKHDS SHDUDQFHRIEXEEOHV7KHHDUFDQDO
Clinical Investigational Plan   Page 21 of 35 
2909-001 Rev C. Entellus Medical Confidential will be observed for edema, fluid/pus, or cerumen (wax). For evaluation, otoscopy finding s will 
be categorized as normal (within normal limits) or abnormal (1 or more characteristic not within 
normal limits). Results  of the otoscopic examination will be documented on the Baseline or 
Follow-up CRF, as appropriate. 
Tympanometry 
Tympanometry will be performed at baseline and at each follow -up visit. The test will be 
performed with a 226 Hz signal and a copy the tympanogr am will be filed with the subject study 
files. The following parameters from the tympanogram will be documented on the Baseline or Follow-up CRF, as appropriate: 
‚Ä¢ Peak pressure (daPa)  
‚Ä¢ Compliance (cm
3) 
‚Ä¢ Ear canal volume (mL)  
‚Ä¢ Type (A, B, or C) 
Valsalva maneuver  
Each subject will attempt to perform a Valsalva maneuver at baseline and at each follow -up visit 
after tympanometry is completed . The maneuver is performed by forcing expiration with closed 
mouth and nostrils  which increases the pressure in the middle ear . This typically result s in 
opening of the Eustachian tube with relief of ear congestion. Popping and/ or clicking are often 
heard during the maneuver. If the subject does not experience clearing, poppi ng, or clicking in 
the ears after attempting the maneuver, the result is considered negative. Results of the Valsalva 
maneuver will be documented as appropriate.  
Ear infection frequency and healthcare visits The number of ear infections experienced in the 12-month period before enrollment will be recorded at the baseline visit. At each follow -up visit, the number of ear infections since the last 
visit will be recorded.  
Similarly, the number of physician/nurse visits for ETD- related issues will be recorded and 
compared between the 12 months before  and 12 months after balloon dilation.  
Subject satisfaction  
At each follow -up visit, balloon dilation and crossover subjects will be asked to indicate their 
satisfaction with the procedure outcome and whether they would recommend the procedure to 
their friends/family.  The subject satisfaction questions will be documented on the ETDQ- 7 CRF, 
which may be considered the source document for the satisfaction ratings. 
Audiologic examination 
An audiologic examination will be performed on all subjects at baseline and on all balloon 
dilation and crossover subjects at the 6-month follow-up.  
Audiometry procedures should be conducted in compliance with the ANSI Method for Manual 
Pure-Tone Threshold Audiometry, ANSI S3.21-1978 (R1997). Computerized or self- recording 
audiometers should be used according to their manufacturer‚Äôs instructions. 
&OLQLFDO,QYHVWLJDWLRQDO3ODQ  3DJHRI
5HY& (QWHOOXV 0HGLFDO&RQILGHQWLDO3XUHWRQHDLUERQHJDSDXGLRP HWU\WHVWLQJZLOOEHSHUIRUPHGX VLQJSXOVHGWRQHV ZLWKWKHEHWWHU
HDULINQRZQWHVWHGILUVW7KHSU HIHUUHGIUHTXHQF\VHTXHQFHV IRUDLUDQGERQHFRQGXFWLRQ
PHDVXUHVDUHVKRZQLQ 7DEOH,IPDVNLQJLVXVHGWKHW\S HDQGOHYHOVKRXOGEHQRWHGRQWKH 
&5)7KHDLUERQHJDSZLOOEHFDO FXODWHGDQGUHSRUWHGRQWKH&5 )
7DEOH3UHIHUUHG)UHTXHQF\+] 7HVWLQJ6HTXHQFHIRU$LUERQH &RQGXFWLRQ7HVWV
Test Order 1 2 3 4 5 6 7 
$LU     D  
%RQH    D   
D :KHQWHVWLQJWKHVHFRQGHDUWKHUHSHDW+]WHVWLVQRWQH FHVVDU\EHIRUHWHVWLQJWKHORZHUIUHTXHQFLHV

Clinical Investigational Plan   Page 23 of 35 
2909-001 Rev C. Entellus Medical Confidential 3 Risk/Benefit Analysis  
3.1 Benefits  
Participation in this study is voluntary; however, information gathered from this study will be 
used to apply for FDA clearance of a new indication for the XprESS device for Eustachian tube 
dilation. Subjects with ETD may experience an improvement in their symptoms. 
3.2 Potential risks  
Study subjects will be informed of all known potential side effects and complications associated 
with study treatment and study assessments before consenting for the study. The risks associated 
with participating in the study are the same as those that the subject would have if treated with 
transnasal  Eustachian tube balloon dilation outside of the study. These potential risks include: 
‚Ä¢ Complication s from anesthesia  ‚Ä¢ Preauricular emphysema  
‚Ä¢ Pain ‚Ä¢ Damage to the ET 
‚Ä¢ Bruising and swelling  ‚Ä¢ Patulous ET  
‚Ä¢ Bleeding ‚Ä¢ Permanent hearing loss  
‚Ä¢ Infection ‚Ä¢ Tympanic membrane damage  
‚Ä¢ Continued or worsening symptoms  ‚Ä¢ Carotid artery damage  
‚Ä¢ Revision surgery  ‚Ä¢ Cerebrospinal fluid leak  
‚Ä¢ Tinnitus  
3.3 Risk mitigation  
The protocol has been developed to minimize  the risks for the subject in a number of ways. 
Sample size was calculated to expose the smallest number of subjects while still being able to adequately test the study objectives. The subject selection criteria were designed  to minimize risk 
by excluding patients who have comorbidities or conditions that may put the patient at higher risk for the balloon dilation procedure. Concomitant procedures that could increase risk and 
confound study results are not permitted during the study. The subjects are closely monitored by 
frequent follow-up visits during the study. Finally, t he selected investigators are experienced in 
endoscopic surgery, specifically trained on use of the XprESS de vice, and expected to comply  
with the manufacturer‚Äôs IFU for the XprESS device for Eustachian tube dilation. 
  
Clinical Investigational Plan   Page 24 of 35 
2909-001 Rev C. Entellus Medical Confidential 4 Device Information  
4.1 Investigational device description  
The device under investigation in this study is the XprESS Multi-Sinus Dilation System 
(XprESS device). The device is  currently a Class I, 510(k)- cleared, commercially available 
device for balloon sinus dilation.  
The XprESS device combines features of a curved suction tip and an ostium seeker with the 
tissue expansi on effect of balloon dilation. The features of this device enable a physician to track 
the device to the Eustachian tubes using endoscopic visualization. The distal end of the devic e is 
re-shapeable, allowing easy a ccess to the Eustachian tubes. The XprESS  curved suction tip has 
an atraumatic ball tip. A suction tube may be connected to the proximal barbed fitting to provide 
active suctio n by covering the suction vent. The XprESS balloon is available in diameters of 3-5 
mm and in lengths of 8, 18, and 20 mm. All sizes are appropriate for treating Eustachian tubes; 
selection is based on physician preference. The XprESS device is provided st erile and for single 
use only. 
4.2 Anticipated changes in device design  
Changes to the device durin g the course of the IDE st udy are not anticipated. If such changes 
occur, Entellus Medical will inform investigators and will submit the appropriate supplemental 
applications to FDA, as necessary.  
4.3 Investigational device management  
Entellus Medical will control the use of the investigational devices by the following activities: 
‚Ä¢ Shipping or hand- carrying devices  only to approved investigators who are participating in 
the study 
‚Ä¢ Maintaining records of shipment and distribution of the devices 
‚Ä¢ Maintaining records of devices used on subje cts and returned devices  
4.4 Device malfunctions  
A device malfunction is defined as a failure of a device to meet its performance specifications or 
otherwise to perform as intended. A malfunction may be a result of any of the following: failure , 
malfunction , improper or inadequate design , manufacturing , labeling, or user error . 
All device malfunctions must be reported  on the Device Malfunction  CRF. All attempts should 
be made to return malfunctioning devices to Entellus Medical for evaluation . Contact the clinical 
monitor for instructions on used device preparation and return procedures. 
  
Clinical Investigational Plan   Page 25 of 35 
2909-001 Rev C. Entellus Medical Confidential 5 Monitoring Procedures  
Entellus Medical personnel or qualified designees will monitor the clinical study  in a manner 
consistent with 21 CFR 812, Subpart C, Responsibilities of Sponsor.  
5.1 Name and address of the Lead Monitor  
Clinical Monitor:  Robyn Schacherer  
 Entellus Medical Inc.  
 3600 Holly Lane North, Suite 40 
 Plymouth, MN 55447 
 Phone: (763) 463-7054 
 Fax: (763) 463-1599 
 E-mail: rschacherer@entellusmedical.com   
Additional designated program monitors may be assigned and contact information provided 
separately.  
5.2 Investigators  
The clinical monitor s will ensure investigators are selected based on their qualifications and 
ability to fulfill the investigator responsibilities. Investigator qualifications and responsibilities 
are outlined in the Investigator Agreement that each investigator must sign before enrolling 
subjects in the study. An updated list of investigators and Institutional Review Boards ( IRBs) 
will be provided to the FDA every 6 months during the study, or as otherwise requested. 
5.3 Investigational center monitoring  
Monitoring visits to the investigational centers will be conducted  frequently during the study to 
ensure that all aspects of the current approved protocol and any amendment(s) are followed. 
Source documents will be reviewed for verification with data on the CRFs and all regulatory 
documents will be checked  for accuracy including but not limited to IRB approvals, study-
related correspondence, and subject  informed consent. The investigator and/or investigational 
center staff must be available to meet with the s ponsor during monitoring visits. 
Upon reasonable notice, t he investigator and i nstitution agree to provide the sponsor 
representatives or designees  and applicable regulatory authorities  with direct access to source 
documents relevant to the study for sponsor quality assurance audit s or inspections by the 
regulatory authorities.  
  
Clinical Investigational Plan   Page 26 of 35 
2909-001 Rev C. Entellus Medical Confidential 6 Adverse Event Definitions and Reporting  
6.1 Adverse event s 
An adverse event (AE) is any undesirable clinical occurrence experienced by the subject during 
the follow-up period regardless of the event‚Äôs relationship to either the study device or the 
procedure. An underlying disease that was present at the time of enrollment is not an AE; 
however, any increase in the severity of an underlying disease is an AE.  All adverse events will 
be reported to FDA in annual progress reports. 
Microtears (<5 mm) of the ET mucosa after balloon dilation in the absence of other undesirable 
effects are not considered adverse events. It is hypothesized that the microtears are related to the 
mechanism of action and are critical to the tissue healing and remodeling o f the ET after balloon 
dilation. 
6.2 Serious adverse event s 
A serious adverse event (SAE) is an event that results in any of the following: 
‚Ä¢ Death 
‚Ä¢ Life-threatening  
‚Ä¢ Hospitalization or prolongation of an existing hospitalization  
‚Ä¢ Invasive surgical intervention to correct or prevent further injury  
‚Ä¢ Persistent or significant disability or incapacity  
‚Ä¢ An important medical event 
An important medical event that may not meet one of the above definitions might be considered as an SAE if it jeopardizes the health of the subject or requires surgical intervention to prevent 
one of the outcomes listed in the above definition. An example of an important medical event is 
postoperative bleeding that requires an intervention such as cautery or additional packing but does not require hospitalization. 
An elective hospitalization/intervention that was planned before the subject enrolled in the study 
is not considered an SAE as defined above. 
6.3 Unanticipated adverse device effect s 
As defined in the IDE regulation 21 CFR 812.3, an unanticipated adverse device effect (UADE) 
is any serious adverse effect on health or safety, or any life-threatening problem or death caused by, or associated with, a device, if that effect was not previously identified in nature, severity, or 
degree of incidence in the protocol, subject informed consent form, or application, or any other 
unanticipated serious problem associated with a device that relates to the rights, safety, or 
welfare of subjects.  
6.4 Assessing, recording, and reporting AEs, SAEs, and UADEs 
An AE m ay be volunteered spontaneously by the subject or discovered as a result of questioning 
or physical examination by the investigator or study staff. The following information should be 
Clinical Investigational Plan   Page 27 of 35 
2909-001 Rev C. Entellus Medical Confidential reported for all AEs as soon as the investigator becomes aware of the event  and updated as 
needed until the event resolves : 
‚Ä¢ Date the AE occurred  
‚Ä¢ Date the investigator (or staff) became aware of the AE  
‚Ä¢ Description of the AE (m ain complaints  or symptoms ) 
‚Ä¢ Relationship to the study device 
‚Ä¢ Relationship to the study procedure 
‚Ä¢ Seriousness 
‚Ä¢ Interventions undertaken 
‚Ä¢ Status of the AE  
Source documents (eg, procedural notes, treatment notes,  clinical summary) may be required as 
supporting documentation for an  AE, SAE, or UADE .  
During the study, all subject deaths must be reported to the s ponsor within 24 hours of the 
investigator‚Äôs (or designated staff‚Äôs) knowledge of the death. Deaths should be reported on the 
End of Study CRF and the event leading to the death reported on an AE CRF. A copy of death 
records, medical records for the event (s) that led to the subject‚Äôs death, death certificate (if 
available) , and an autopsy report (if performed) should be deidentified and sent to the sponsor as 
soon as they become available.  
  
Clinical Investigational Plan   Page 28 of 35 
2909-001 Rev C. Entellus Medical Confidential 7 Protocol D eviations  
Investigators are required to adhere to t he study protocol, signed Investigator Agreement, 
applicable national or local laws and regulations, and any conditions required by the applicable 
IRB or regulatory authority.  
A protocol deviation is used to describe situations in which the protocol was not followed 
(including all required activities at each scheduled visit or activities occurring outside of the study windows). All attempts should be made to obtain sponsor approval for deviations before 
their occurrence.  
An investigator must notify the sponsor and the applicable IRB of any deviation from the study 
protocol done to protect the life or physical well- being of a subject (medical emergencies). Such 
notice should be given within 24 hours. The sponsor will determine if the subject affected is 
eligible to continue in the study. 
Documentation of deviations identified by the investigational center, the monitor, or other 
sponsor representative(s) will be entered onto the Protocol Deviation CRF for the purpose of tracking compliance with the protocol. The investigational centers will be required to document 
actions taken to prevent recurrence of deviations. The sponsor representative will initiate 
corrective actions based on individual deviations or trending reports, as appropriate. 
  
Clinical Investigational Plan   Page 29 of 35 
2909-001 Rev C. Entellus Medical Confidential 8 Labeling  
Entellus Medical will modify the existing FDA-cleared labeling (package labels and IFU 
documents) for the XprESS device to include the required investigational device statement 
(below), the indication statement , risks, and treatment procedure specific to E ustachian tube 
dilation. 
The following statement will be included on the outer packaging unit and the IFU as required by 
21 CFR 812.5: 
‚Ä¢ CAUTION- Investigational Device. Limited by Federal (or United States) law to 
investigational use.  
  
Clinical Investigational Plan   Page 30 of 35 
2909-001 Rev C. Entellus Medical Confidential 9 Administrative Information  
9.1 Investigational center selection  
The study will be conducted at up to 7 investigational centers in the US. Centers will be 
evaluated to ensure each  center has the capacity and capability to obtain informed consent and 
comply with all protocol requirements. The investigators and investigational center personnel are 
required to comply with the principles of Good Clinical Practices (GCP) as described in the FDA 
regulations. 
9.2 Training  
The training of investigational center  personnel will be the responsibility of the sponsor or 
sponsor-authorized representatives.  All treating physicians must be proficient in the use of 
endoscopic techniques. All physicians will be trained on the preparation and use of the XprESS 
device before subject enrollment in this study.  
To insure uniform data collection and protocol compliance, the sponsor or sponsor-authorized 
representatives wi ll review all components of the study with the study coordinator(s)/study s taff 
at each investigational center. The review will  include the study protocol, techniques for the 
identification of eligible patients, instructions  for data collection during the procedure, and 
schedules for follow-up. 
9.3 Informed consent process  
Informed consent must be obtained in accordance with US regulation 21 CFR 50. The subject s 
must be informed about their right to withdraw from the study at any time and for any reason 
without sanction, penalty, or loss of benefits to which the subject  is otherwise entitled and also 
informed that withdrawal from the study will not jeopard ize their future medical care. The 
standard institutional patient consent form does not replace the study informed consent form 
(ICF). 
The sponsor will provide a study-specific ICF template to each investigational center  for IRB 
submission. Thi s template may be modified to suit the requirements  of the individual 
investigational center. The s ponsor must pre approve all changes to the ICF  before initial 
submission to the IRB. The IRB -approved consent form must be sent to and approved by the 
sponsor before the first device shipment . One approved copy must be retained in the 
investigational center ‚Äôs study files  along with the other investigational forms.  
Each enrolled subject must be given a copy of the ir signed consent form and  another copy must 
be retained in the investigational center study file for that subject . Informed consent documents 
must be available for review by the s ponsor during monitoring visits. 
Modifications to the study- specific ICF and/or any other written information distributed to 
subjects must be pre approved by the s ponsor and the IRB , as necessary.  
Clinical Investigational Plan   Page 31 of 35 
2909-001 Rev C. Entellus Medical Confidential 9.4 Confidentiality  
All information and data sent to the sponsor concerning subjects or their participation in this 
study will be considered confidential. Subjects will be identified by a study -specific 
identification code. All data used in the analysis and reporting of this investigation  will use the 
study-specific codes and will not include identifiable references to individual subject s. Any 
source documentation must be deidentified by the investigational center before being sent to the 
sponsor.  
The investigator will allow  visits by the s ponsor representatives and the US FDA inspectors or 
any other local governmental body to review the study subjects‚Äô medical records, including test 
or laboratory data that might have been recorded on diagnostic test media (eg , CT scan). 
9.5 Institutional Review Board (IRB)  
It is the investigator‚Äôs responsibility to obtain and maintain written approval of the final 
investigational plan  and ICF from the applicable IRB. The investigator is responsible for 
submitting and obtaining initial and continuing review of the study by the IRB. It is also the 
investigator‚Äô s responsibility to notify the IRB of any amendments to these documents. W ritten 
IRB approval must identify the study by title and version,  document the date of review, and be 
forwarded to the sponsor before the first device shipment.  
The investigator must keep all study-related correspondence with the IRB on file and forward 
copies of such correspondence to the sponsor. 
9.6 Investigator responsibilities  
The investigator for each investigational center  is responsible for ensuring the study is conducted 
according to:  
‚Ä¢ All signed agreements  
‚Ä¢ The study protocol 
‚Ä¢ IRB guidelines 
‚Ä¢ Applicable local and federal  regulations 
The investigator for each center  may not begin enrollment until the s ponsor receives and 
approves (when necessary) required documents, including the signed Investigator Agreement 
and the IRB approvals of the investigational plan and ICF. 
It is acceptable for the i nvestigator to delegate 1 or more of the above functions to a 
subinvestigator or trained study coordinator; however, the investigator remains responsible for 
the proper conduct of the clinical investigation, including obtaining informed consent , collecting 
all required data, and submitting  accurate and complete CRFs . 
At each investigational center, appropriate procedures must be followed to maintain subject  
confidentiality according to HIPAA (Health Insurance Portability and Accountability A ct) 
regulations. Each center may have its own internal procedures or requirements for use and 
release of subject medical information in research studies. Each i nvestigator is responsible for 
Clinical Investigational Plan   Page 32 of 35 
2909-001 Rev C. Entellus Medical Confidential obtaining appropriate approvals, consents, or releases of medical information as dictated by their 
relevant patient privacy laws.  
The study is not transferable to other centers /facilities attended by the i nvestigator unless 
preapproval is obtained from the applicable IRB and the sponsor. 
9.7 Sponsor responsibilities 
The sponsor‚Äôs responsibilities for this study are to: 
‚Ä¢ Provide sufficient training to participating investigational centers  to support study 
activities according to the agreements executed with the centers  
‚Ä¢ Select all clinical investigators and investigational centers and other consultants (eg, the 
study monitors) who participate in the study 
‚Ä¢ Provide financial support to each center according to the agreements executed with each center 
‚Ä¢ Follow/prom ote all regulatory standards according to  local/federal regulations for the 
investigational center s, core laboratories, and other participants, and ensure regular 
investigational center  monitoring to assure compliance with the regulations  
‚Ä¢ Retain ownership of all clinic al data generated in this study and control the use of the 
data for appropriate purposes only 
‚Ä¢ Review and approve publication of study results in the literature  
‚Ä¢ Ensure timely and appropriate study registration in a public clinical trial database (eg, 
Clinicaltrials.gov), if applicable  
9.8 Criteria for terminating study  
The sponsor reserves the right to terminate the study early but intends only to exercise this right 
for valid scientific or administrative reasons or reasons related to the protection of study subjects. 
Investigators, applicable IRBs, and FDA will be notified in writing in the event of study 
termination. Reasons for study termination include but are not limited to: 
‚Ä¢ The discovery of an unexpected, significant, or unacceptable risk to the study subjects  
‚Ä¢ A decision on the part of the sponsor to suspend or discontinue commercial distribution 
of the device 
9.9 Criteria for terminating an investigational center  
The sponsor reserves the right to stop enrollment of subjects  at a particular investigational center 
at any time after the study initiation visit f or any of the fol lowing reasons : 
‚Ä¢ Repeated failure to complete CRFs in a timely manner  
‚Ä¢ Failure to obtain appropriate informed consent 
‚Ä¢ Failure to report any study subjec t deaths, SAEs, or UADEs within the timeframes 
specified in Table 3 
‚Ä¢ Loss of or unaccounted product inventory 
‚Ä¢ Repeated protocol deviations 
‚Ä¢ Lack of study enroll ment or study activity  
&OLQLFDO,QYHVWLJDWLRQDO3ODQ  3DJHRI
5HY& (QWHOOXV 0HGLFDO&RQILGHQWLDO10Reports and Records 
10.1Records 
,QDFFRUGDQFHZLWK&)5GD OOUHFRUGVSHUWDLQLQJWR WKHFOLQLFDOVWXG\ZLOOEHNHSW
IRUDPLQLPXPRI\HDUVIROORZL QJWKHGDWHRQZKLFKWKHVWXG\ LVWHUPLQDWHGRUFRPSOHWHG,IDQ
LQYHVWLJDWRUZLVKHVWRZLWKGUDZ IURPWKHUHVSRQVLELOLW\RIPDLQ WDLQLQJWKHVHVWXG\UHFRUGVD
WUDQVIHURIWKDWUHVSRQVLELOLW\WRDSHUVRQZLOOLQJWRDFFHSWW KHUHVSRQVLELOLW\DVRXWOLQHGLQ
&)5PXVWRFFXUDQGEHUH SRUWHGWRWKHVSRQVRUQRWPRUH WKDQGD\VDIWHUWKHWUDQVIHU
RFFXUV
10.2Reporting requirements 
7DEOHVKRZVDVXPPDU\RIDOOLQYHVWLJ DWRUUHSRUWLQJUHTXLUHPHQWV,Q DGGLWLRQWRWKLVOLVW
LQGLYLGXDO,5%VPD\DGGDGGLWLRQD OUHSRUWLQJUHTXLUHPHQWVDQGR UUHTXLUHDGLIIHUHQWQRWLILFDWLRQ
WLPHIUDPH7KHSULQFLSDOLQYHVWLJDWRUDWHDFKLQYHVWLJDWLRQDO FHQWHULVUHVSRQVLEOHIRUHQVXULQJ
DQ\DGGLWLRQDOORFDO,5%UHSRUWLQJUHTXLUHPHQWVDUHPHW
7DEOH6XPPDU\RI,QYHVWLJDW RU5HSRUWLQJ5HTXLUHPHQWV
Type of reportPrepared by
Investigator for: Notification time frame
8QDQWLFLSDWHG$GYHUVH'HYLFH(IIHFW8$'( 6SRQVRU	,5% :LWKLQ ZRUNLQJGD\VRINQRZOHGJH
)DLOXUHWRREWDLQLQIRUPHGFRQVHQWSULRUWRGHYLFH
XVH6SRQVRU	,5% :LWKLQZRUNLQJGD\V
:LWKGUDZDORI,5%DSSURYDO 6SRQVRU :LWKLQZRUNLQJGD\VRINQR ZOHGJH
6XEMHFWZLWKGUDZDO 6SRQVRU :LWKLQZRUNLQJGD\VRINQRZOHGJH
)LQDOUHSRUW 6SRQVRU	,5%:LWKLQPRQWKVDIWHUFRPSOHWLRQRU
WHUPLQDWLRQ
3URJUHVVUHSRUW 6SRQVRU	,5% $WPLQLPXPDQQXDOO\
'HYLDWLRQVGXHWRHPHUJHQF\ 6SRQVRU	,5% :LWKLQZRUNLQJGD\V RIHPHUJHQF\

7DEOHOLVWVWKHVSRQVRUUHSRUWLQJUHTXLUHPHQWVDQGQRWLILFDWLRQWLPH IUDPHV
&OLQLFDO,QYHVWLJDWLRQDO3ODQ  3DJHRI
5HY& (QWHOOXV 0HGLFDO&RQILGHQWLDO7DEOH6XPPDU\RI6SRQVRU 5HSRUWLQJ5HTXLUHPHQWV
Type of report Prepared by Sponsor  for: Notification time frame
8QDQWLFLSDWHG$GYHUVH'HYLFH(IIHFW8$'( )'$ :LWKLQZRUNLQJ GD\VRIUHFHLSW
)DLOXUHWRREWDLQLQIRUPHGFRQVHQWSULRUWR
GHYLFHXVH)'$ :LWKLQZRUNLQJGD\VRIUHFHLSW
:LWKGUDZDORI,5%DSSURYDO )'$ :LWKLQZRUNLQJGD\VRIUHFHLSW 
:LWKGUDZDORI)'$DSSURYDO ,QYHV WLJDWRUV	,5% :LWKLQZRUNLQJ GD\VRIUHFHLSW
5HFDOOVDQGGHYLFHGLVSRVLWLRQ )'$	,5% :LWKLQZRUNLQJGD\V DIWHUUHTXHVW
)LQDOUHSRUW )'$,5%	,QYHVWLJDWRUVPRQWKVDIWHUFRPSOHWLRQRUWHUPLQDWLRQ
RIVWXG\
3URJUHVVUHSRUWV )'$	,5% $QQXDOO\
&XUUHQWLQYHVWLJDWRUOLVW )'$  PRQWKLQWHUYDOVDIWHU)'$DSSU RYDO
6WXG\FRPSOHWLRQRUWHUPLQDWLRQ )'$:LWKLQGD\VRIFRPSOHWLRQRU
WHUPLQDWLRQ
  
Clinical Investigational Plan   Page 35 of 35 
2909-001 Rev C. Entellus Medical Confidential 11 Referenc es 
1  Seibert JW, Danner CJ. Eustachian tube function and the middle ear. Otolaryngol Clin N Am . 
2006;39:1221-1235. 
2  Bluestone CD. Eustachian Tube: Structure, Function, Role in Otitis Media . Hamilton, 
Ontario, Canada: BC Decker, Inc.; 2005.  
3  Poe DS, Hanna BMN. Balloon dilation of the cartilaginous portion of the eustachian tube: 
initial safety and feasibility analysis in a cadaver model. Am J Otolaryngol . 2011;32:115-
123. 
                                                  